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The POZ domain is an evolutionarily conserved protein–protein interaction
domain that is found in approximately 40 mammalian transcription factors. POZ
domains mediate both homodimerization and the heteromeric interactions of
different POZ-domain transcription factors with each other. Miz1 is a POZ-
domain transcription factor that regulates cell-cycle arrest and DNA-damage
responses. The activities of Miz1 are altered by its interaction with the POZ-
domain transcriptional repressors BCL6 and NAC1, and these interactions have
been implicated in tumourigenesis in B-cell lymphomas and in ovarian serous
carcinomas that overexpress BCL6 and NAC1, respectively. A strategy for the
puriﬁcation of tethered POZ domains that form forced heterodimers is
described, and crystal structures of the heterodimeric POZ domains of Miz1/
BCL6 and of Miz1/NAC1 are reported. These structures will be relevant for the
design of therapeutics that target POZ-domain interaction interfaces.
1. Introduction
Many eukaryotic transcription factors function as biological dimers,
and individual members of transcription-factor networks may form
distinct homodimeric and heterodimeric associations that influence
the recognition of target gene DNA sequences and the recruitment of
transcriptional co-regulators. The speciﬁcity and regulation of tran-
scription-factor dimerization thereby play critical roles in controlling
the gene expression patterns that govern proliferation and differ-
entiation in many cell lineages.
The POZ [poxvirus and zinc ﬁnger, also known as BTB (bric-a`-
brac, tram-track and broad complex)] domain is a protein–protein
interaction domain that is found at the N-terminus of approximately
40 mammalian transcription factors (Bardwell & Treisman, 1994;
reviewed in Stogios et al., 2005). Many POZ-domain transcription
factors (POZ-TFs) play roles in development and several have been
implicated in speciﬁc human malignancies (reviewed in Kelly &
Daniel, 2006). The POZ-domain fold comprises an -helical core that
is flanked by -strands, and the transcription-factor POZ domains
form highly stable obligate dimers that contain a central hydrophobic
interface of -helices, together with two -sheet interfaces that each
contain one strand contributed from each constituent monomer (Li et
al., 1997). The POZ domains also mediate the recruitment of non-
POZ partners such as transcriptional co-regulators, and most POZ-
TFs interact with DNA via a zinc-ﬁnger domain that is well separated
from the POZ domain by a flexible linker.
Miz1 (Myc-interacting zinc-ﬁnger protein) is a POZ-domain tran-
scription factor (Peukert et al., 1997) that activates target genes via
recruitment of the cofactors p300 (Staller et al., 2001) and nucleo-
phosmin (Wanzel et al., 2008). Many Miz1 target genes play roles in
cell proliferation (Seoane et al., 2001; Staller et al., 2001) and differ-
entiation (Wu et al., 2003; Kime & Wright, 2003), and Miz1 activates
the cell-cycle inhibitor gene cdkn1a in response to DNA damage
(Herold et al., 2002; Seoane et al., 2002). Miz1 is also an important
regulator of autophagy (Wolf et al., 2013) and of B-cell and T-cell
development (Kosan et al., 2010; Mo¨ro¨y et al., 2011; Saba, Kosan,
Vassen, Klein-Hitpass et al., 2011; Saba, Kosan, Vassen &
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Moroy, 2011). The transcriptional properties of Miz1 are modulated
by its interaction with other transcription factors, and many of these
associations are directly relevant in human malignancy. Miz1 acts as a
repressor when complexed with the bHLH-LZ transcription factor c-
Myc (Peukert et al., 1997), and the inappropriate repression of Miz1
target genes contributes to deregulated cell proliferation in c-Myc-
overexpressing tumours (Ho¨nnemann et al., 2012; van Riggelen et al.,
2010); the interaction of Miz1 with c-Myc is mediated by residues
located adjacent to its zinc-ﬁnger DNA-binding domain. Miz1
associates with other POZ-domain transcription factors via hetero-
meric POZ–POZ interactions, and these interactions are also
important in normal development and in malignancy. Miz1 interacts
with the POZ-domain transcriptional repressor BCL6 (B-cell
lymphoma 6) in germinal centre B cells (Phan et al., 2005), leading to
repression of the Miz1 target gene cdkn1a; this facilitates the
proliferative expansion that normally takes place in spite of the
natural DNA damage that accompanies the somatic hypermutation
and class-switch recombination of immunoglobulin genes at this
stage. However, the overexpression of BCL6 in diffuse large B-cell
lymphoma (DLBCL) and follicular lymphoma leads to the inap-
propriate repression of Miz1 target genes and may contribute to
malignancy. More recently, it has been recognized that Miz1 interacts
with other POZ-domain transcription factors, including ZBTB4
(Weber et al., 2008) and NAC1 (nucleus accumbens-associated 1;
Stead & Wright, 2014), and the inappropriate repression of Miz1-
target genes may therefore also be relevant to oncogenesis in NAC1-
overexpressing ovarian serous carcinomas (Nakayama et al., 2006).
Although all transcription-factor POZ domains crystallize as homo-
dimers (Ahmad et al., 1998, 2003; Ghetu et al., 2008; Stead et al., 2008,
2009; Rosbrook et al., 2012; Schubot et al., 2006; Li et al., 1999; Stogios
et al., 2010, 2007), the Miz1 POZ domain also crystallized in a
tetrameric form that resulted from the interaction of two classic POZ
dimers (Stead et al., 2007). This observation raised the suggestion that
heteromeric POZ-domain interactions might be mediated by a
tetrameric association of different POZ dimers. Recent cross-linking
studies have, however, indicated a heterodimeric interaction of the
Miz1 and NAC1 POZ domains in transfected mammalian cells (Stead
& Wright, 2014).
Structural studies of the BCL6 POZ domain (Ahmad et al., 2003;
Ghetu et al., 2008) are guiding the design of targeted therapies for
DLBCL, and crystal structures of the dimeric BCL6 POZ domain in
complex with the co-repressors SMRT (silencing mediator for reti-
noid and thyroid hormone receptors) and BCoR (BCL6-interacting
co-repressor) have been used to identify small molecules that block
these interactions and that kill BCL6-positive B-cell lymphoma cells
in vitro and in vivo (Cerchietti et al., 2009, 2010). No structures of
heterodimeric POZ domains have been reported, and this may reflect
difﬁculties in the production of pure heterodimeric forms. The crys-
tallization of heterodimeric transcription factors is often hampered
by the predominance of homodimers in bacterial co-expression
systems, and alternative strategies are often used. For example, the
puriﬁcation of heterodimers of the bHLH-Zip protein Max with its
bHLH-zip partners Myc or Mad was achieved using a semi-synthetic
scheme for the production of chemoselectively ligated heterodimers
(Nair & Burley, 2003).
In nature, flexible Gly-rich linkers sometimes separate the multiple
domains of a single protein (Argos, 1990; Steinert et al., 1991), and
synthetic Gly-rich linkers have been used in protein-engineering
strategies to separate two binding partners within a chimeric protein
(reviewed by Reddy Chichili et al., 2013). The increased proximity of
the binding partners favours intramolecular over intermolecular
interactions, and forced dimers therefore predominate. This approach
has been used for the production of tethered homodimers and
heterodimers both in bacteria and in mammalian cells. For example, a
forced homodimer of the HIV protease was expressed in bacteria for
structural and biochemical studies (Wlodawer et al., 1989; Cheng et
al., 1990); the forced dimer was more stable than the natural protease
dimer, and this strategy provided a means of studying the effect of
monomer–dimer transitions on enzymatic activity and of producing
asymmetric dimer mutants for structure–function studies. In
mammalian cells, the ectopic expression of forced homodimers and
heterodimers has been particularly useful for dissecting the interac-
tions between family members of transcription-factor networks:
forced homodimers of the transcription factor Nanog have been used
to study the relative importance of dimers and monomers in stem-cell
self-renewal and pluripotency (Wang et al., 2008), and tethered
heterodimers have been used to analyse the role of the bHLH
proteins MyoD and E47 in myogenesis (Neuhold & Wold, 1993).
Here, we describe a strategy for the production of heterodimeric
POZ domains by using a Gly+Ser-rich tether to separate two
different POZ domains within a chimeric protein, and we report the
crystal structures of the heterodimeric POZ domains of Miz1/BCL6
and Miz1/NAC1.
2. Materials and methods
2.1. Cloning
Tethered POZ domains that formed forced heterodimers were
expressed as GST-fusion proteins using the plasmid pGEX-6P-1
(GE Healthcare). The oligonucleotides 50-AATTCAGATCTG-
GCGGAGGCTCGAGCGGTGGGAGCGGTACCG and 50-TC-
GACGGTACCGCTCCCACCGCTCGAGCCTCCGCCAGATCTG
were annealed and inserted between the EcoRI and SalI restriction-
enzyme sites of pGEX-6P-1; this sequence encoded a polypeptide
tether. A cDNA encoding human Miz1 residues 2–115 was inserted
between the BamHI and BglII sites located at the 50 end of this
region, and cDNAs encoding human BCL6 residues 5–129 or human
NAC1 residues 2–125 were inserted between the KpnI and SalI sites
at the 30 end. NAC1 contained the F98D mutation that enhances the
solubility of the recombinant protein (Stead et al., 2009). The
resulting plasmids encoded the Miz1 POZ domain joined to either the
BCL6 or NAC1 POZ domain by a flexible in-frame polypeptide
tether (Arg-Ser-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Ser-Gly-Thr).
2.2. Protein expression and purification
Plasmids were transformed into Escherichia coli BL21 (DE3)
pLysS cells and plated onto Luria–Bertani agar plates containing
34 mg ml1 chloramphenicol and 100 mg ml1 ampicillin. A single
colony was cultured overnight at 310 K with shaking in 2TY
supplemented with the same antibiotics. 84 ml of the overnight
culture was diluted into 12 l 2TY supplemented with 100 mg ml1
ampicillin and the cells were grown at 310 K with shaking to an
optical density at 600 nm of 0.7. Expression of recombinant protein
was induced by the addition of isopropyl -d-1-thiogalactopyranoside
to a ﬁnal concentration of 0.1 mM and the culture was incubated at
289 K for 16 h. Cells were harvested by centrifugation and resus-
pended in phosphate-buffered saline (PBS) containing 5 mM
dithiothreitol (DTT).
Cells were lysed using a cell disruptor (Constant Systems) and
Triton X-100 was added to a ﬁnal concentration of 0.1%. The lysate
was clariﬁed by centrifugation at 39 000g for 20 min and the super-
natant was passed through a 1.2 mm ﬁlter. Fusion proteins were
bound to Super-Glu glutathione resin (Generon) equilibrated with
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binding buffer (PBS, 0.1% Triton X-100, 5 mMDTT) for 1 h at 277 K.
Nonspeciﬁcally bound proteins were removed from the resin by
alternating washes with binding buffer and with binding buffer
supplemented with 1M NaCl. The glutathione resin was further
rinsed with 20 mM Tris–HCl, 75 mM NaCl, 5 mM DTT pH 7.5, and
the GST tag was removed by cleavage with PreScission protease
overnight at 277 K. POZ domains were further puriﬁed by size-
exclusion chromatography on a pre-equilibrated HiLoad Superdex 75
26/60 column (GE Healthcare) in 20 mM Tris–HCl, 150 mM NaCl,
5 mM DTT, 5% glycerol pH 7.5. Puriﬁed proteins were concentrated
to 6 mg ml1 using Vivaspin 20 centrifugal concentrators (Sartorius).
Protein concentration was determined using the Bradford reagent.
The yield of puriﬁed protein was approximately 1 mg per litre of
bacterial culture.
2.3. Protein crystallization
Crystallization trials were set up in Corning 3552 96-well plates
using a variety of commercially available sparse-matrix crystallization
screens.
Crystals of the Miz1/BCL6 heterodimeric POZ domain were
obtained in 8.25% polyethylene glycol (PEG) 3350, 4.95% 2-
propanol, 0.2M ammonium citrate pH 4.5 using a protein concen-
tration of 3.5 mg ml1. Optimization of this condition was carried out
by hanging-drop vapour diffusion in 24-well plates using dichloro-
dimethylsilane-treated coverslips. Crystals with average dimensions
of 100  70  70 mm were grown by mixing 2.5 ml protein solution at
3.5 mg ml1 with 2.5 ml reservoir solution (4% PEG 3350, 3% 2-
propanol, 0.2M ammonium citrate pH 4.5) and incubating at 291 K
for 5 d. Crystals were harvested using a nylon cryo-loop and trans-
ferred for 30 s to a 5 ml drop of mother liquor supplemented with 15%
glycerol before being flash-cooled at 100 K.
Crystals of the Miz1/NAC1 heterodimeric POZ domain were
obtained in 0.33% PEG 4000, 0.33M ammonium citrate pH 5.5 using
a protein concentration of 7 mg ml1. Optimization of this condition
was carried out by sitting-drop vapour diffusion using 24-well Intelli-
Plates (Art Robbins). Crystals with average dimensions of 200  100
 100 mm were grown by mixing 3 ml protein at 3.5 mg ml1 with
2.5 ml reservoir solution (0.2% PEG 4000, 0.1M sodium citrate pH
5.6) and incubating at 291 K for 5 d. Crystals were harvested as above
using mother liquor supplemented with 25% glycerol.
2.4. Data processing
X-ray data were collected on Diamond Light Source beamline I04
and were processed, reduced and scaled with XDS (Kabsch, 2010)
and AIMLESS (Evans & Murshudov, 2013) as part of the xia2
pipeline (Winter, 2010). The structure of the Miz1/BCL6 POZ-
domain heterodimer was solved by molecular replacement using
structural communications
Acta Cryst. (2014). F70, 1591–1596 Stead & Wright  Heterodimeric POZ domains of Miz1/BCL6 and Miz1/NAC1 1593
Table 1
Data collection and processing.
Values in parentheses are for the outer shell.
Miz1/BCL6 Miz1/Nac1
PDB entry 4u2m 4u2n
Crystal parameters
Space group P212121 P21212
Unit-cell parameters (A˚, ) a = 91.85, b = 97.88,
c = 119.88,
 =  =  = 90
a = 109.09, b = 115.19,
c = 58.29,
 =  =  = 90
Data collection
Resolution range (A˚) 58.47–2.23 (2.29–2.23) 50.93–2.30 (2.36–2.30)
Wavelength (A˚) 0.97949 0.97949
Rmerge† (%) 4.6 (31.1) 3.0 (66.3)
Rp.i.m.‡ (%) 2.5 (17.3) 1.7 (37.0)
hI/(I)i 19 (4.8) 24 (2.4)
Total No. of reflections 215105 (14633) 133634 (10182)
No. of unique reflections 52962 (3738) 33315 (2420)
Multiplicity 4.1 (3.9) 4.0 (4.2)
Completeness (%) 99.3 (96.2) 99.7 (99.7)
Reﬁnement
Resolution (A˚) 2.23 2.30
Rwork§ (%) 21.1 23.8
Rfree} (%) 24.0 28.6
R.m.s.d.†† bond angles () 1.502 1.623
R.m.s.d.†† bond lengths (A˚) 0.015 0.017
No. of non-H protein atoms 7187 3581
No. of water molecules 163 30
Average B factor (A˚2) 47.0 66.0
Ramachandran favoured‡‡ (%) 98.2 98.5
Ramachandran outliers‡‡ (%) 0 0
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of
the ith measurement of reflection hkl and hI(hkl)i is the mean intensity
of all i measurements. ‡ Rp.i.m. =
P
hklf1=½NðhklÞ  1g
1=2P
i jIiðhklÞ  hIðhklÞij=P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of the ith measurement of the reflection
hkl, hI(hkl)i is the mean intensity of all i measurements and N(hkl) is the
multiplicity. § Rwork =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where Fobs and Fcalc are the
observed and calculated structure factors, respectively. } Rfree is the same as Rwork but
calculated using a random 5% of the data that was excluded from reﬁne-
ment. †† R.m.s.d. is the deviation from ideal values. ‡‡ Ramachandran analysis
was called out in MolProbity (Chen et al., 2010).
Figure 1
Structures of heterodimeric POZ domains. Ribbon representations of (a) the Miz1/
BCL6 (PDB entry 4u2m, chain D) and (b) the Miz1/NAC1 (PDB entry 4u2n, chain
B) heterodimeric POZ domains. The Miz1 residues are coloured green and the
BCL6 and NAC1 residues are coloured orange and purple, respectively. Secondary-
structure elements of BCL6 and of NAC1 are shown, together with the 5 strand of
Miz1; the unstructured region that corresponds to NAC1 6 is indicated in
parentheses. The dashed lines denote the linkers between the POZ domains; the
electron density in these regions was poor and the residues were not modelled in
the structures.
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Phaser (McCoy et al., 2007) with the Miz1 and BCL6 POZ-domain
monomers as search models [Miz1, PDB entry 3m52, chain A resi-
dues 2–50 (Stogios et al., 2010); BCL6, PDB entry 1r28, chain A
residues 7–128 (Ahmad et al., 2003)]. Phaser located a Miz1/BCL6
POZ-domain heterodimer that resembled the structures of reported
POZ-domain dimers; this was then used as a model in Phaser to ﬁnd
all four copies of the heterodimeric POZ domain in the asymmetric
unit. Density modiﬁcation was carried out using Parrot (Zhang et al.,
1997) and the model was built using ARP/wARP (Cohen et al., 2008).
The structure of the Miz1/NAC1 heterodimer was solved by
molecular replacement using the Miz1/BCL6 POZ-domain hetero-
dimer as the search model; the asymmetric unit contained two Miz1/
NAC1 POZ-domain heterodimers.
The models of the heterodimeric Miz1/BCL6 and Miz1/NAC1
POZ domains underwent iterative reﬁnement in REFMAC5
(Murshudov et al., 2011) and model building using Coot (Emsley et al.,
2010). Stereochemistry was analysed with MolProbity (Chen et al.,
2010).
SSM structure superpositions were calculated in CCP4mg
(McNicholas et al., 2011) and contact residues were obtained using
the PISA server (Krissinel & Henrick, 2007). Illustrations of protein
structures were prepared using CCP4mg.
3. Results
3.1. Bacterial expression of tethered POZ domains
To obtain crystal structures of heterodimeric POZ domains, we
expressed chimeric proteins that contained the Miz1 POZ domain
joined to either the BCL6 or the NAC1 POZ domain by a Gly+Ser-
rich linker that was predicted to form a flexible hydrophilic tether.
The Miz1 POZ domain was placed at the N-terminus of the chimeric
proteins, as reasoned from the structures of homodimeric POZ
domains. The BCL6 and NAC1 POZ domains each contain six -
helices and ﬁve -strands, with the N-terminal 1 of each chain
interacting with 5 of the opposite chain; the N-terminus of each
chain is therefore close to the C-terminus of the opposite chain in the
domain-swapped homodimer. The Miz1 POZ domain lacks a 1
strand, and the N- and C-termini of the opposite chains of the
homodimer are further apart. It was therefore anticipated that the
formation of forced heterodimers would be more favoured if the
Miz1 POZ domain were positioned at the N-terminus rather than at
the C-terminus of the chimeric proteins.
The tethered Miz1/BCL6 and Miz1/NAC1 POZ domains eluted at
the same volume as classic POZ-domain homodimers when puriﬁed
by size-exclusion chromatography.
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Figure 2
Superpositions of heterodimeric POZ domains. (a) Stereoimage of the superpositions of the Miz1/BCL6 heterodimeric POZ domain (blue; PDB entry 4u2m, chain D) with
the homodimeric POZ domains of Miz1 (green; PDB entry 2q81 chains A and B) and of BCL6 (orange; PDB entry 1r28). (b) Stereoimage of the superpositions of the Miz1/
NAC1 heterodimeric POZ domain (blue; PDB entry 4u2n, chain B) with the homodimeric POZ domains of Miz1 (green; PBD entry 2q81 chains A and B) and of NAC1
(purple; PDB entry 3ga1, Stead et al., 2009). (c) Superposition of Miz1 POZ-domain monomers from PDB entries 2q81 chain A (blue), 2q81 chain B (yellow), 4u2m chainD
residues 2–115 (green) and 4u2n chain B residues 2–115 (red).
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3.2. Crystal structures of heterodimeric Miz1/BCL6 and Miz1/NAC1
POZ domains
The tethered POZ domains crystallized readily, and structures
were determined by molecular replacement using the constituent
POZ-domain monomers as search models; structures of Miz1/BCL6
and of Miz1/NAC1 were determined to 2.2 and to 2.3 A˚ resolution,
respectively (Table 1 and Fig. 1).
The tethered POZ domains formed forced heterodimers that
resemble the overall structure of reported POZ-domain homodimers.
The heterodimeric POZ domain of Miz1/BCL6 superposed well with
the homodimeric POZ domains of Miz1 and BCL6 (r.m.s.d. values of
2.0 and 1.14 A˚2, respectively), and the heterodimeric POZ domain of
Miz1/NAC1 superposed well with the Miz1 and NAC1 homodimers
(r.m.s.d. values of 1.86 and 1.66 A˚2, respectively; Figs. 2a and 2b). The
6 region of the NAC1 chain was unstructured in the heterodimeric
Miz1/NAC1 POZ domain, as observed in the NAC1 homodimer. The
N-terminal 1 strands of the BCL6 and NAC1 POZ domains interact
with 5 of the opposite chain in the domain-swapped homodimers,
and although the Miz1 POZ domain lacks a 1 strand, its 5 region
interacts with 1 of BCL6 or NAC1 in the heterodimeric POZ
complexes.
In most POZ-domain homodimers, the secondary-structure
elements 2, 3 and 4 form a three-stranded -sheet that is located
at the ‘top’ of the molecule; however, in Miz1 the 4 region is
displaced relative to the 2 and 3 strands in the crystal structures of
Miz1 POZ-domain homodimers and tetramers. Each constituent
dimer of the Miz1 POZ-domain tetramer (PDB entry 2q81; Stead et
al., 2007) contains one ‘normal’ and one ‘displaced’ 4 region (Fig. 2c,
chain B and chain A, respectively), and the position of these
displaced 4 strands was similar to that subsequently reported in a
structure of the Miz1 POZ homodimer (PDB entry 3m52; Stogios et
al., 2010). The Miz1 4 region of the heterodimeric Miz1/BCL6 and
Miz1/NAC1 POZ domains is located between the previously
described ‘normal’ and ‘displaced’ positions, indicating that this
region is flexible (Fig. 2c).
The dimerization interfaces of the heterodimeric POZ domains
resemble those of POZ-domain homodimers, comprising the central
hydrophobic interface of -helices together with the strand-
exchanged -sheet interface (1–50; Fig. 1) that is found on one side
only of the POZ-domain heterodimers. Several of the residues
involved in hydrogen-bond interactions at the interface of the Miz1
homodimer (PDB entry 3m52) are involved in similar interactions in
the Miz1/BCL6 and Miz1/NAC1 heterodimers. For example, Phe3
and His6 of Miz1 1 each interact with 4 residues of the opposite
chain in the Miz1 homodimer and in both the Miz1/BCL6 and Miz1/
NAC1 heterodimers. Other common interactions involve the Miz1 1
residue Gln17, which interacts with 2 of the opposite chain, and the
Miz1 4 residues Ala80 and Leu82, which interact with 1.
4. Conclusion
The interaction of the Miz1 POZ domain with the POZ-domain
transcriptional repressors BCL6 and NAC1 leads to the repression of
Miz1 target genes and is relevant in human malignancy. The tran-
scriptional co-repressors BCoR and SMRT bind to the lateral groove
of the BCL6 POZ domain and make contacts with residues from both
chains of the BCL6 POZ homodimer; notably, these residues are not
conserved in the Miz1 chain of the Miz1/BCL6 heterodimer. The
production of a forced POZ-domain heterodimer of Miz1/BCL6 will
enable a direct experimental analysis of its co-repressor interactions,
and these structures will inform the design of therapeutic inhibitors.
The network of heteromeric interactions between POZ-domain
transcription factors has not been extensively studied and the struc-
tures of forced POZ-domain heterodimers will reveal features that
determine the speciﬁcity of these associations.
We thank the staff of beamline I04 at Diamond Light Source for
advice on X-ray data collection. This work was funded by Yorkshire
Cancer Research (grant reference L334).
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